Grufity logoGrufity logo
StocksFundsSearch Filings

Madrigal Pharmaceuticals Inc Stock Research

MDGL

280.02USD-4.86(-1.71%)Market Closed

Market Summary

USD280.02-4.86
Market Closed
-1.71%

MDGL Stock Price

MDGL RSI Chart

MDGL Valuation

Market Cap

5.1B

Price/Earnings (Trailing)

-16.27

Price/Sales (Trailing)

2.5K

Price/Free Cashflow

-19.75

MDGL Price/Sales (Trailing)

MDGL Profitability

Return on Equity

-149.63%

Return on Assets

-81.46%

Free Cashflow Yield

-5.06%

MDGL Fundamentals

MDGL Revenue

MDGL Earnings

Earnings (TTM)

-314.7M

Earnings Y/Y

-33.7%

Earnings Q/Q

10.48%

Price Action

52 Week Range

57.21322.67
(Low)(High)

Last 7 days

-0.8%

Last 30 days

-10.2%

Last 90 days

0.3%

Trailing 12 Months

307.7%

MDGL Financial Health

Current Ratio

3.12

Debt/Equity

6.25

Debt/Cashflow

-3.21

MDGL Investor Care

Shares Dilution (1Y)

6.90%

Diluted EPS (TTM)

-18.1

Peers (Alternatives to Madrigal Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
311.1B
1.6B
-10.47% 70.40%
-162.26
199.76
77.54% 1.62%
285.4B
56.7B
-9.71% -7.25%
24.12
4.92
0.03% -39.22%
87.6B
12.4B
-9.13% 5.17%
20.2
7.2
-25.07% -47.28%
83.8B
9.2B
-4.53% 18.84%
25.7
9.1
15.86% 32.99%
23.2B
1.0B
-6.40% 45.93%
-21.75
22.33
22.88% -19.27%
11.6B
975.7M
1.67% 67.21%
-10.42
11.92
27.41% -212.78%
9.6B
2.0B
-10.84% -12.99%
13.17
4.84
12.05% 52.86%
MID-CAP
5.1B
-
-10.25% 307.66%
-16.27
2.5K
- -27.52%
3.4B
204.6M
10.50% 0.21%
-5.87
16.66
-7.52% 10.65%
3.4B
363.3M
10.85% -0.47%
-4.8
9.35
3.39% -55.81%
2.2B
18.9M
-16.27% -6.81%
-2.93
114.18
- -16.17%
SMALL-CAP
3.6B
-
1.50% -9.34%
-8.36
38.06
34.30% -67.22%
1.2B
256.5M
-27.45% 57.57%
12.31
4.77
66.85% 120.61%
288.8M
165.3M
-32.22% 33.43%
-3.16
1.75
130.70% 57.97%
37.4M
-
1.03% 2894.60%
-0.74
19.11
- -29.84%

Financials for Madrigal Pharmaceuticals

Income Statement (Last 12 Months)
Description(%) Q/Q2021Q42021Q32021Q22021Q12020Q4
Revenue-51.1%363,000743,0001,506,0002,619,0004,329,000
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-8.3%332363159216223
  Current Assets-8.3%331361157215221
    Cash Equivalents-65.8%11333259.0053.0042.00
  Net PPE-14.8%1.001.001.001.001.00
Liabilities10.4%18216514813377.00
  Current Liabilities-15.1%98.0011699.0084.0077.00
  Long Term Debt-67.00----
    LT Debt, Non Current70.4%84.0049.0049.0049.00-
Shareholder's Equity-23.9%15019711.0084.00146
  Retained Earnings-8.0%-1,039-962-876-795-724
  Additional Paid-In Capital2.6%1,1901,160888880871
Shares Outstanding1.0%18.0018.0017.0017.0017.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-15.2%-259-224-214-200-190
  Share Based Compensation11.9%35.0032.0030.0028.0028.00
Cashflow From Investing-117.5%-36.1020715613184.00
Cashflow From Financing16.8%36631369.0090.00104

Risks for MDGL

What is the probability of a big loss on MDGL?

95.4%


Probability that Madrigal Pharmaceuticals stock will be more than 20% underwater in next one year

89.2%


Probability that Madrigal Pharmaceuticals stock will be more than 30% underwater in next one year.

59.2%


Probability that Madrigal Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MDGL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Madrigal Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for MDGL

Cumulative Returns on MDGL

0.8%


10-Year Cumulative Returns

56.4%


7-Year Cumulative Returns

1.1%


5-Year Cumulative Returns

34.1%


3-Year Cumulative Returns

What are the long-term rolling returns for MDGL?

FIve years rolling returns for Madrigal Pharmaceuticals.

Annualized Returns

Which funds bought or sold MDGL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-26
ProShare Advisors LLC
reduced
-9.73
-218,464
667,669
-%
2023-05-25
Legato Capital Management LLC
new
-
488,154
488,154
0.09%
2023-05-24
Verity Asset Management, Inc.
added
44.23
60,455
357,091
0.21%
2023-05-23
Capital Impact Advisors, LLC
added
17.85
-11,658
700,616
0.86%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-8.39
-97,397
317,603
-%
2023-05-18
JPMORGAN CHASE & CO
reduced
-1.81
-2,850,000
12,947,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-19.02
-2,033,000
4,240,000
0.01%
2023-05-16
Hudson Bay Capital Management LP
new
-
6,226,080
6,226,080
0.03%
2023-05-16
JANE STREET GROUP, LLC
added
161
15,112,200
27,906,400
0.01%
2023-05-16
FRED ALGER MANAGEMENT, LLC
added
29.44
376,167
5,055,000
0.03%

1–10 of 37

Latest Funds Activity

Are funds buying MDGL calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own MDGL
No. of Funds

Madrigal Pharmaceuticals News

The Motley Fool
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87 ....
The Motley Fool,
20 hours ago
The Motley Fool
Investopedia
The Motley Fool
Why These 3 Nasdaq Stocks Buckled Today.
The Motley Fool,
14 days ago
The Motley Fool

Schedule 13G FIlings of Madrigal Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
armistice capital, llc
1.21%
208,000
SC 13G/A
Feb 14, 2023
deep track capital, lp
0%
0
SC 13G/A
Feb 14, 2023
baker bros. advisors lp
9.0%
1,545,113
SC 13G/A
Feb 14, 2023
avoro capital advisors llc
9.7%
1,660,000
SC 13G/A
Feb 09, 2023
vanguard group inc
7.40%
1,266,375
SC 13G/A
Feb 06, 2023
wellington management group llp
0.19%
31,830
SC 13G/A
Feb 02, 2023
state street corp
7.37%
1,260,993
SC 13G
Feb 01, 2023
blackrock inc.
5.8%
986,572
SC 13G/A
May 19, 2022
deep track capital, lp
5.37%
917,825
SC 13G
Feb 15, 2022
armistice capital, llc
6.6%
1,124,000
SC 13G

MDGL Fair Value

Show Fair-Value

Recent SEC filings of Madrigal Pharmaceuticals

View All Filings
Date Filed Form Type Document
May 09, 2023
8-K
Current Report
May 09, 2023
8-K
Current Report
May 09, 2023
424B5
Prospectus Filed
May 09, 2023
10-Q
Quarterly Report
May 01, 2023
DEFA14A
DEFA14A
May 01, 2023
DEF 14A
DEF 14A
Apr 21, 2023
PRE 14A
PRE 14A
Mar 03, 2023
10-K/A
Annual Report
Mar 02, 2023
4
Insider Trading
Feb 23, 2023
8-K
Current Report

Latest Insider Trading transactions for MDGL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-01
Waltermire Robert E.
acquired
439,600
87.92
5,000
senior vp, chief pharma dev.
2023-03-01
Waltermire Robert E.
sold
-1,372,080
274
-5,000
senior vp, chief pharma dev.
2023-02-28
Waltermire Robert E.
acquired
439,600
87.92
5,000
senior vp, chief pharma dev.
2023-02-28
Waltermire Robert E.
sold
-1,360,360
272
-5,000
senior vp, chief pharma dev.
2023-01-17
Levy Richard S
acquired
2,316,840
103
22,489
-
2023-01-17
Levy Richard S
sold
-6,592,690
293
-22,489
-
2023-01-16
Howarth Alex G.
acquired
-
-
15,001
chief financial officer
2023-01-16
FRIEDMAN PAUL A
acquired
-
-
26,668
chief executive officer
2023-01-16
Taub Rebecca
acquired
-
-
20,001
pres., r&d, and cmo
2023-01-16
Lynch Brian Joseph
acquired
-
-
15,001
svp and general counsel

1–10 of 41

Paul A. Friedman
70
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

MDGL Income Statement

2023-03-31
Condensed Consolidated Statements Of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:  
Total revenues
Operating expenses:  
Research and development62,15447,929
General and administrative16,1829,658
Total operating expenses78,33657,587
Loss from operations(78,336)(57,587)
Interest income3,77669
Interest expense(2,336)0
Net loss$ (76,896)$ (57,518)
Net loss per common share:  
Basic net loss per common share$ (4.23)$ (3.36)
Diluted net loss per common share$ (4.23)$ (3.36)
Basic weighted average number of common shares outstanding18,187,92417,103,395
Diluted weighted average number of common shares outstanding18,187,92417,103,395

MDGL Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 113,308$ 331,549
Marketable securities216,16927,225
Prepaid expenses and other current assets1,8072,595
Total current assets331,284361,369
Property and equipment, net512601
Right-of-use asset653602
Total assets332,449362,572
Current liabilities:  
Accounts payable12,12823,831
Accrued expenses85,56791,461
Lease liability653602
Total current liabilities98,348115,894
Long term liabilities:  
Loan payable, net of discount83,96549,289
Total long term liabilities83,96549,289
Total liabilities182,313165,183
Stockholders' equity:  
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at March 31, 2023 and December 31, 2022; 2,369,797 and 2,369,797 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively 
Common stock, par value $0.0001 per share authorized: 200,000,000 at March 31, 2023 and December 31, 2022; 18,283,074 and 18,102,523 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively22
Additional paid-in-capital1,189,7761,160,079
Accumulated other comprehensive loss(86)(32)
Accumulated deficit(1,039,556)(962,660)
Total stockholders' equity150,136197,389
Total liabilities and stockholders' equity$ 332,449$ 362,572